Profile data is unavailable for this security.
About the company
Genoway SA is a France-based company which is specializes in the provision of genetically modified mouse and rat models for biopharmaceutical companies, laboratories and research institutes. The Company offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
- Revenue in EUR (TTM)21.42m
- Net income in EUR1.26m
- Incorporated1999
- Employees128.00
- LocationGenoway SATechnopark 2, 31 Rue Saint Jean-de-DieuLYON 69007FranceFRA
- Phone+33 437654100
- Fax+33 437654101
- Websitehttps://www.genoway.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poxel SA | 1.98m | -35.09m | 12.27m | 22.00 | -- | -- | -- | 6.19 | -1.08 | -1.08 | 0.0591 | -1.27 | 0.1002 | -- | 5.09 | 90,045.45 | -177.50 | -52.39 | -- | -92.20 | 0.0505 | -- | -1,771.33 | -299.15 | -- | -1.39 | -- | -- | 193.92 | -49.84 | -11.76 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 2.53m | 1.09m | 13.70m | 27.00 | 12.34 | -- | 8.69 | 5.41 | 0.9967 | 0.9967 | 2.32 | -- | -- | -- | -- | 93,777.41 | -- | -3.53 | -- | -4.39 | 110.03 | 134.21 | 43.01 | -33.16 | -- | 12.90 | -- | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Predilife SA | 317.79k | -4.22m | 15.55m | 19.00 | -- | -- | -- | 48.92 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Phaxiam Therapeutics SA | 2.14m | -21.92m | 17.22m | 54.00 | -- | 0.6763 | -- | 8.04 | -3.46 | -3.46 | 0.3956 | 2.54 | 0.0409 | -- | 8.56 | 41,980.39 | -41.90 | -50.69 | -61.11 | -66.25 | -- | -- | -1,023.96 | -1,009.09 | -- | -70.91 | 0.4556 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Oncodesign Precision Medicine Opm SA | 468.73k | -7.78m | 18.46m | 19.00 | -- | 5.86 | -- | 39.39 | -0.449 | -0.449 | 0.0269 | 0.1733 | 0.0311 | -- | 0.4553 | 21,305.91 | -51.68 | -- | -85.27 | -- | 153.18 | -- | -1,660.23 | -- | -- | -360.87 | 0.715 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Nfl Biosciences SAS | 0.00 | -2.37m | 19.18m | 4.00 | -- | 5.51 | -- | -- | -0.2653 | -0.2653 | 0.00 | 0.3584 | 0.00 | -- | -- | 0.00 | -44.70 | -83.27 | -70.88 | -122.37 | -- | -- | -- | -- | -- | -- | 0.0151 | -- | -- | -- | -53.28 | -- | -- | -- |
| Valbiotis SA | 527.00k | -8.94m | 19.55m | 52.00 | -- | 1.16 | -- | 37.10 | -0.6571 | -0.6571 | 0.0373 | 1.07 | 0.0208 | 2.52 | 0.2447 | 10,134.62 | -35.21 | -32.92 | -46.61 | -46.36 | -511.95 | 53.15 | -1,697.15 | -418.87 | 4.54 | -91.62 | 0.266 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| Fermentalg SA | 8.04m | -14.14m | 25.42m | 58.00 | -- | 0.6626 | -- | 3.16 | -0.2787 | -0.2787 | 0.1521 | 0.4452 | 0.1395 | 1.34 | 4.82 | 129,629.00 | -22.80 | -21.94 | -25.70 | -24.71 | 14.04 | 14.73 | -163.46 | -248.95 | 3.42 | -53.95 | 0.2639 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
| genOway SA | 21.42m | 1.26m | 34.78m | 128.00 | 26.14 | 1.84 | 9.28 | 1.62 | 0.1435 | 0.1435 | 2.45 | 2.04 | 0.6658 | 1.39 | 3.26 | 161,089.30 | 3.90 | 0.2166 | 5.40 | 0.3048 | 92.34 | 94.82 | 5.86 | 0.4177 | 1.81 | -- | 0.2639 | -- | 17.55 | 13.16 | 101.55 | 22.35 | -14.31 | -- |
| Gensight Biologics SA | 804.00k | -20.11m | 36.81m | 11.00 | -- | -- | -- | 45.79 | -0.3537 | -0.3537 | 0.0123 | -0.2402 | 0.0507 | -- | 21.73 | 50,250.00 | -126.79 | -79.44 | -- | -144.54 | -- | -- | -2,501.00 | -1,036.27 | -- | -1,250.38 | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Novacyt SA | 22.31m | -44.90m | 40.96m | 240.00 | -- | 0.4836 | -- | 1.84 | -0.6357 | -0.6405 | 0.3159 | 1.20 | 0.1603 | -3.66 | 1.02 | 82,619.26 | -32.27 | 10.94 | -38.44 | 14.49 | 153.78 | 61.98 | -201.27 | 17.64 | 3.82 | -23.91 | 0.1573 | -- | -44.97 | -0.9408 | -25.22 | -- | 2.09 | -- |
| Abionyx Pharma SA | 4.86m | -3.36m | 43.52m | 61.00 | -- | 4.25 | -- | 8.96 | -0.1063 | -0.1063 | 0.1548 | 0.2934 | 0.3316 | 21.80 | 6.05 | 80,264.46 | -22.93 | -18.82 | -33.15 | -28.87 | 19.19 | 14.32 | -69.15 | -128.54 | 2.22 | -114.07 | 0.2513 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
Data as of Nov 22 2024. Currency figures normalised to Genoway SA's reporting currency: Euro EUR
0.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Chaussier Gestion SAas of 27 Sep 2024 | 16.00k | 0.17% |
Data from 27 Sep 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
